Repository logo
 
Publication

Expression of mTOR in normal and pathological conditions

2023-07Journal article Open access
Simple item page
dc.contributor.authorMarques-Ramos, Ana
dc.contributor.authorCervantes, Renata
dc.date.accessioned2023-08-01T11:09:33Z
dc.date.available2023-08-01T11:09:33Z
dc.date.issued2023-07
dc.descriptionThe H&TRC authors gratefully acknowledge the FCT/MCTES national support through the UIDB/05608/2020 and UIDP/05608/2020. This work was part of the IPL/2021/GATumor_ESTeSL project.pt_PT
dc.description.abstractThe mechanistic/mammalian target of rapamycin (mTOR), a protein discovered in 1991, integrates a complex pathway with a key role in maintaining cellular homeostasis. By comprising two functionally distinct complexes, mTOR complex 1 (mTORC1) and mTORC2, it is a central cellular hub that integrates intra- and extracellular signals of energy, nutrient, and hormone availability, modulating the molecular responses to acquire a homeostatic state through the regulation of anabolic and catabolic processes. Accordingly, dysregulation of the mTOR pathway has been implicated in a variety of human diseases. While major advances have been made regarding the regulators and effectors of the mTOR signaling pathway, insights into the regulation of mTOR gene expression are beginning to emerge. Here, we present the currently available data regarding the mTOR expression regulation at the level of transcription, translation, and mRNA stability and systematize the current knowledge about the fluctuations of mTOR expression observed in several diseases, both cancerous and non-cancerous. In addition, we discuss whether mTOR expression changes can be used as a biomarker for diagnosis, disease progression, prognosis, and/or response to therapeutics. We believe that our study will contribute to the implementation of new disease biomarkers based on mTOR as it gives an exhaustive perspective on the regulation of mTOR gene expression in both normal and pathological conditions.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationMarques-Ramos A, Cervantes R. Expression of mTOR in normal and pathological conditions. Mol Cancer. 2023;22(1):112.pt_PT
dc.identifier.doi10.1186/s12943-023-01820-zpt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/16353
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSpringer Naturept_PT
dc.relationIPL/2021/GATumor_ESTeSLpt_PT
dc.relation.publisherversionhttps://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-023-01820-zpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectmTOR biomarkept_PT
dc.subjectmTOR expressionpt_PT
dc.subjectmTOR expression cancerpt_PT
dc.subjectmTOR expression diseasept_PT
dc.subjectmTOR mRNA stabilitypt_PT
dc.subjectmTOR transcriptional regulationpt_PT
dc.subjectmTOR translation regulationpt_PT
dc.subjectIPL/2021/GATumor_ESTeSLpt_PT
dc.subjectFCT_UIDB/05608/2020pt_PT
dc.subjectFCT_UIDP/05608/2020pt_PT
dc.titleExpression of mTOR in normal and pathological conditionspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue1pt_PT
oaire.citation.startPage112pt_PT
oaire.citation.titleMolecular Cancerpt_PT
oaire.citation.volume22pt_PT
person.familyNameWellenkamp de Carvalho Freire de Cervantes
person.givenNameRenata
person.identifier.ciencia-id6018-3CC9-B640
person.identifier.orcid0000-0001-5990-4168
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication28678633-1f6a-4b79-8150-12a857f4a531
relation.isAuthorOfPublication.latestForDiscovery28678633-1f6a-4b79-8150-12a857f4a531

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Expression of mTOR in normal and pathological conditions.pdf
Size:
1.95 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Artigos